ALEC
NASD Alector, Inc.$1.77 ↓ -0.05 (-2.49%) Trading Down from the previous close of $1.81, $0.04 below the day’s high of $1.80
- YTD change
- +13.14%
- vs 20-day SMA
- -10.45%
- vs 200-day SMA
- -11.64%
Price ranges
Price & Performance
-0.66 (-26.72%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 95.9% away from all-time highs of $43.32
- ALEC is up 13% since the beginning of the year
- ALEC is down 43% over the past 12 months
- ALEC is down 29% over the past 1 month
- 6% of all ALEC investors are betting against ALEC
ALEC reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -41.0%.
- Previous minute
- +$0.00
- Last hour
- -$0.02
- Last 5 days
- -5.61%
- vs 8-day SMA
- -6.24%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.